J S Skyler

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi request reprint Prediction and prevention of type 1 diabetes: progress, problems, and prospects
    J S Skyler
    Diabetes Research Institute, NIDDK Type 1 Diabetes TrialNet Clinical Trials Network, University of Miami Miller School of Medicine, Miami, Florida, USA
    Clin Pharmacol Ther 81:768-71. 2007
  2. doi request reprint Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
    Tihamer Orban
    Corresponding author Jay S Skyler
    Diabetes Care 37:1069-75. 2014
  3. doi request reprint B-lymphocyte depletion with rituximab and β-cell function: two-year results
    Mark D Pescovitz
    Corresponding author Jay S Skyler
    Diabetes Care 37:453-9. 2014
  4. pmc Primary and secondary prevention of Type 1 diabetes
    J S Skyler
    Division of Endocrinology, Diabetes and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Diabet Med 30:161-9. 2013
  5. ncbi request reprint Pulmonary insulin delivery--state of the art 2007
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Diabetes Technol Ther 9:S1-3. 2007
  6. doi request reprint Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami, 1450 NW 10th Avenue, Suite 3054, Miami, FL 33136, United States
    Diabetes Res Clin Pract 82:238-46. 2008
  7. pmc Type 1 Diabetes TrialNet--an international collaborative clinical trials network
    Jay S Skyler
    Diabetes Research Institute, Miami, Florida 33101 6960, USA
    Ann N Y Acad Sci 1150:14-24. 2008
  8. pmc Update on worldwide efforts to prevent type 1 diabetes
    Jay S Skyler
    Diabetes Research Institute, Miami, Florida 33101 6960, USA
    Ann N Y Acad Sci 1150:190-6. 2008
  9. doi request reprint Immune intervention for type 1 diabetes mellitus
    J S Skyler
    Division of Endocrinology, Diabetes and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Int J Clin Pract Suppl . 2011
  10. ncbi request reprint Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, FL 33136, USA
    Diabetes Care 30:579-85. 2007

Detail Information

Publications36

  1. ncbi request reprint Prediction and prevention of type 1 diabetes: progress, problems, and prospects
    J S Skyler
    Diabetes Research Institute, NIDDK Type 1 Diabetes TrialNet Clinical Trials Network, University of Miami Miller School of Medicine, Miami, Florida, USA
    Clin Pharmacol Ther 81:768-71. 2007
    ..Given this sequence of events, for which it is possible to envision intervention to interdict the process, it is not surprising that much research effort has been expended to identify individuals at risk of the disease...
  2. doi request reprint Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
    Tihamer Orban
    Corresponding author Jay S Skyler
    Diabetes Care 37:1069-75. 2014
    ..The beneficial effect was sustained for at least 1 year after cessation of abatacept infusions or 3 years from T1D diagnosis. ..
  3. doi request reprint B-lymphocyte depletion with rituximab and β-cell function: two-year results
    Mark D Pescovitz
    Corresponding author Jay S Skyler
    Diabetes Care 37:453-9. 2014
    ..Subjects were followed further to determine whether there was persistence of effect...
  4. pmc Primary and secondary prevention of Type 1 diabetes
    J S Skyler
    Division of Endocrinology, Diabetes and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Diabet Med 30:161-9. 2013
    ..Interventions tested include nicotinamide, insulin injections, oral insulin, nasal insulin, glutamic acid decarboxylase, and cyclosporine. Underway are secondary prevention studies with teplizumab and with abatacept...
  5. ncbi request reprint Pulmonary insulin delivery--state of the art 2007
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Diabetes Technol Ther 9:S1-3. 2007
  6. doi request reprint Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami, 1450 NW 10th Avenue, Suite 3054, Miami, FL 33136, United States
    Diabetes Res Clin Pract 82:238-46. 2008
    ..To assess pulmonary safety during discontinuation and readministration of inhaled human insulin (EXU; Exubera((R)) insulin human [rDNA origin]) Inhalation Powder) therapy in adults with type 1 diabetes...
  7. pmc Type 1 Diabetes TrialNet--an international collaborative clinical trials network
    Jay S Skyler
    Diabetes Research Institute, Miami, Florida 33101 6960, USA
    Ann N Y Acad Sci 1150:14-24. 2008
    ....
  8. pmc Update on worldwide efforts to prevent type 1 diabetes
    Jay S Skyler
    Diabetes Research Institute, Miami, Florida 33101 6960, USA
    Ann N Y Acad Sci 1150:190-6. 2008
    ..These have tested nicotinamide, parenteral insulin, oral insulin, nasal insulin, and the elimination of cow's milk from infant feeding...
  9. doi request reprint Immune intervention for type 1 diabetes mellitus
    J S Skyler
    Division of Endocrinology, Diabetes and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA
    Int J Clin Pract Suppl . 2011
    ..All immune intervention studies reported in this time frame were included. In addition, the author selected other relevant articles dealing with mechanisms, markers, triggers, and pathology of human type 1 diabetes...
  10. ncbi request reprint Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, FL 33136, USA
    Diabetes Care 30:579-85. 2007
    ..The purpose of this study was to evaluate the long-term (2-year) safety and efficacy of inhaled human insulin (Exubera [insulin human (rDNA origin)] inhalation powder) (EXU) in adult patients with type 1 diabetes...
  11. ncbi request reprint Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial
    Jay S Skyler
    University of Miami, School of Medicine, Miami, FL 33136, USA
    Diabetes Care 28:1630-5. 2005
    ..We investigated whether a basal/bolus insulin regimen involving rapid-acting, dry powder, inhaled insulin could provide glycemic control comparable with a basal/bolus subcutaneous regimen...
  12. ncbi request reprint Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study
    J S Skyler
    Department of Medicine, University of Miami School of Medicine, FL, USA
    Lancet 357:331-5. 2001
    ..Inhaled intrapulmonary delivery of insulin offers a potential new way to deliver meal-related insulin, eliminating the need for preprandial injections...
  13. ncbi request reprint Diabetes trends in the USA
    Jay S Skyler
    Pediatrics and Psychology, Division of Endocrinology, University of Miami, Miami, FL 33136, USA
    Diabetes Metab Res Rev 18:S21-6. 2002
    ..On an arbitrary gradient scale of 1 to 4 (with 1 being primitive and 4 being comprehensive), the US is only at stage 2 for diabetes care systems, indicating a pressing need for improvement in diabetes care...
  14. ncbi request reprint Microvascular complications. Retinopathy and nephropathy
    J S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    Endocrinol Metab Clin North Am 30:833-56. 2001
    ..With such medical management, appropriate intervention can occur to reduce the risk of blindness and renal failure and to lessen the burden from diabetic retinopathy and nephropathy...
  15. ncbi request reprint Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1
    Jay S Skyler
    University of Miami, PO Box 016960 D 110, Miami, FL 33101 6960, USA
    Diabetes Care 28:1068-76. 2005
    ..This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes...
  16. ncbi request reprint Pulmonary insulin update
    Jay S Skyler
    University of Miami, Miami, Florida 33136, USA
    Diabetes Technol Ther 7:834-9. 2005
  17. pmc Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 32:1603-7. 2009
    ..We studied the incidence of dysglycemia and its prediction of the development of type 1 diabetes in islet cell autoantibody (ICA)-positive individuals. In addition, we assessed whether dysglycemia was sustained...
  18. pmc Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 33:620-5. 2010
    ..001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes...
  19. pmc A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Pediatr Diabetes 12:85-90. 2011
    ..We assessed whether differing autoantibody screening criteria for type 1 diabetes (T1D) prevention trials result in different baseline metabolic profiles of those who screen positive...
  20. pmc Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1)
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes 59:2386-9. 2010
    ..We characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied whether those fluctuations are related to the early C-peptide response to oral glucose...
  21. pmc Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 31:2188-92. 2008
    ..We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial-Type 1 (DPT-1) participants...
  22. ncbi request reprint Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial
    Barry E Hurwitz
    Behavioral Medicine Research Center, University of Miami, c o VA Medical Center, FL 33125, USA
    Arch Intern Med 167:148-54. 2007
    ..Despite findings that selenium supplementation may improve immune functioning, definitive evidence of its impact on human immunodeficiency virus (HIV) disease severity is lacking...
  23. ncbi request reprint Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 29:643-9. 2006
    ..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis...
  24. ncbi request reprint HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure
    Barry E Hurwitz
    Behavioral Medicine Research Center, Division of Endocrinology and Metabolism, University of Miami, Miami, FL 33125, USA
    Cardiovasc Toxicol 4:303-16. 2004
    ....
  25. ncbi request reprint A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 31:528-33. 2008
    ..The accurate prediction of type 1 diabetes is essential for appropriately identifying prevention trial participants. Thus, we have developed a risk score for the prediction of type 1 diabetes...
  26. ncbi request reprint Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
    ....
  27. ncbi request reprint Insulin therapy in type II diabetes: who needs it, how much of it, and for how long?
    J S Skyler
    Division of Endocrinology, University of Miami School of Medicine, FL 33136, USA
    Postgrad Med 101:85-90, 92-4, 96. 1997
    ..On the other hand, beta-cell failure is progressive, and with long duration of diabetes, permanent insulin therapy may be necessary to achieve satisfactory glucose control...
  28. ncbi request reprint Diabetes mellitus: pathogenesis and treatment strategies
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami D 110, 1450 NW 10th Avenue, Suite 3061, Miami, Florida 33136, USA jskyler miami edu
    J Med Chem 47:4113-7. 2004
    ..This article introduces the disease state of diabetes mellitus and provides a background of the impact of the disease on the population, its biology and pathophysiology, and the current treatment strategies for treating diabetes...
  29. ncbi request reprint C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
    Jerry P Palmer
    Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 53:250-64. 2004
    ..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome...
  30. doi request reprint Central obesity and insulin resistance in the cardiometabolic syndrome: pathways to preclinical cardiovascular structure and function
    Johanna R Klaus
    Behavioral Medicine Research Center, University of Miami, Miami, FL 33136, USA
    J Cardiometab Syndr 4:63-71. 2009
    ..The findings suggest predominant pathways through which subclinical metabolic processes may exert pathogenic impact on the heart and vasculature...
  31. ncbi request reprint Modeling preclinical cardiovascular risk for use in epidemiologic studies: Miami community health study
    R Z Goldstein
    Behavioral Medicine Research Center, University of Miami, Miami, FL, USA
    Am J Epidemiol 154:765-76. 2001
    ..These findings indicate that preclinical cardiovascular disease risk may involve pathophysiologic processes in which cardiac inotropic and vasodilatory functions are linked to specific aspects of insulin metabolic syndrome...
  32. ncbi request reprint Hypertension in patients with diabetes mellitus
    J S Skyler
    Department of Medicine, University of Miami, Florida, USA
    Am J Hypertens 8:100s-105s. 1995
    ..The drugs that increase insulin sensitivity also tend to improve dyslipidemia or remain lipid neutral. In contrast, those drugs that tend to impair insulin sensitivity also tend to worsen dyslipidemia...
  33. doi request reprint Prevention of type 1 diabetes: the time has come
    Jennifer Sherr
    Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
    Nat Clin Pract Endocrinol Metab 4:334-43. 2008
    ..In this Review we discuss risk-stratification techniques and how they are applied, other diagnostic criteria, and outcomes from diabetes-prevention trials...
  34. doi request reprint Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment
    Stephen W Ponder
    Children s Diabetes and Endocrine Center of South Texas, Corpus Christi, Texas, USA
    Diabetes Educ 34:327-33. 2008
    ..The purpose of this review study was to determine and categorize common causes of intermittent hyperglycemia and suggest potential measures to prevent and treat the identified causes...
  35. ncbi request reprint Cellular therapy for type 1 diabetes: has the time come?
    Jay S Skyler
    JAMA 297:1599-600. 2007
  36. doi request reprint Thirty years of diabetes care: reflections on the beginning
    Jay S Skyler
    Diabetes Care 31:183-4. 2008